CD44 as a cancer stem cell marker and its prognostic value in patients with ovarian carcinoma

References

• Afify AM, Ferguson AW, Davila RM, Werness BA. 2001. Expression of CD44S and CD44v5 is more common in stage III than in stage I serous ovarian carcinomas. Applied Immunohistochemistry & Molecular Morphology 9:309–314.
   Web of Science ®Google Scholar
• Aruffo A, Stamenkovic I, Melnick M, Underhill CB, Seed B. 1990. CD44 is the principal cell surface receptor for hyaluronate. Cell 61:1303–1313.
   PubMed Web of Science ®Google Scholar
• Bonneau C, Rouzier R, Geyl C, Cortez A, Castela M, Lis R, et al. 2015. Predictive markers of chemoresistance in advanced stages epithelial ovarian carcinoma. Gynecologic Oncology 136:112–120.
   PubMed Web of Science ®Google Scholar
• Curley MD, Garrett LA, Schorge JO, Foster R, Rueda BR. 2011. Evidence for cancer stem cells contributing to the pathogenesis of ovarian cancer. Frontiers in Bioscience 16:368–392.
   Web of Science ®Google Scholar
• Elzarkaa AA, Sabaa BE, Abdelkhalik D, Mansour H, Melis M, Shaalan W, et al. 2016. Clinical relevance of CD44 surface expression in advanced stage serous epithelial ovarian cancer: a prospective study. Journal of Cancer Research and Clinical Oncology 142:949–958.
   PubMed Web of Science ®Google Scholar
• Garson K, Vanderhyden BC. 2015. Epithelial ovarian cancer stem cells: underlying complexity of a simple paradigm. Reproduction (Cambridge, England) 149:R59–R70.
   PubMed Web of Science ®Google Scholar
• Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, Caceres-Cortes J, et al. 1994. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 367:645–648.
   PubMed Web of Science ®Google Scholar
• Meng E, Long B, Sullivan P, McClellan S, Finan MA, Reed E, et al. 2012. CD44+/CD24– ovarian cancer cells demonstrate cancer stem cell properties and correlate to survival. Clinical & Experimental Metastasis 29:939–948.
   PubMed Web of Science ®Google Scholar
• Motohara T, Fujimoto K, Tayama S, Narantuya D, Sakaguchi I, Tashiro H, et al. 2016. CD44 variant 6 as a predictive biomarker for distant metastasis in patients with epithelial ovarian cancer. Obstetrics and Gynecology 127:1003–1011.
   PubMed Web of Science ®Google Scholar
• Oberaigner W, Minicozzi P, Bielska-Lasota M, Allemani C, De Angelis R, Mangone L, et al. 2012. Survival for ovarian cancer in Europe: the across-country variation did not shrink in the past decade. Acta Oncologica 51:441–453.
   PubMed Web of Science ®Google Scholar
• Pylvas-Eerola M, Liakka A, Puistola U, Koivunen J, Karihtala P. 2016. Cancer stem cell properties as factors predictive of chemoresistance in neoadjuvantly-treated patients with ovarian cancer. Anticancer Research 36:3425–3431.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Rodriguez L, Sancho-Torres I, Mesonero C, Gibbon DG, Shih WJ, Zotalis G. 2003. The CD44 receptor is a molecular predictor of survival in ovarian cancer. Medical Oncology (Northwood, London, England) 20:255–263.
   PubMed Web of Science ®Google Scholar
• Sacks JD, Barbolina MV. 2015. Expression and function of CD44 in epithelial ovarian carcinoma. Biomolecules 5:3051–3066.
   PubMed Web of Science ®Google Scholar
• Sillanpaa S, Anttila MA, Voutilainen K, Tammi RH, Tammi MI, Saarikoski SV, et al. 2003. CD44 expression indicates favorable prognosis in epithelial ovarian cancer. Clinical Cancer Research 9:5318–5324.
   PubMed Web of Science ®Google Scholar
• Sosulski A, Horn H, Zhang L, Coletti C, Vathipadiekal V, Castro CM, et al. 2016. CD44 splice variant v8–10 as a marker of serous ovarian cancer prognosis. PLoS One 11:e0156595.
   PubMed Web of Science ®Google Scholar
• Tjhay F, Motohara T, Tayama S, Narantuya D, Fujimoto K, Guo J, et al. 2015. CD44 variant 6 is correlated with peritoneal dissemination and poor prognosis in patients with advanced epithelial ovarian cancer. Cancer Science 106:1421–1428.
   PubMed Web of Science ®Google Scholar
• Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. 2015. Global cancer statistics, 2012. CA: A Cancer Journal for Clinicians 65:87–108.
   PubMed Web of Science ®Google Scholar
• Wang YC, Yo YT, Lee HY, Liao YP, Chao TK, Su PH, et al. 2012. ALDH1-bright epithelial ovarian cancer cells are associated with CD44 expression, drug resistance, and poor clinical outcome. The American Journal of Pathology 180:1159–1169.
   PubMed Web of Science ®Google Scholar
• Winter WE, 3rd, Maxwell GL, Tian C, Carlson JW, Ozols RF, Rose PG, et al. 2007. Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology 25:3621–3627.
   PubMed Web of Science ®Google Scholar
• Zhang J, Chang B, Liu J. 2013. CD44 standard form expression is correlated with high-grade and advanced-stage ovarian carcinoma but not prognosis. Human Pathology 44:1882–1889.
   PubMed Web of Science ®Google Scholar